The European stock market has been buzzing with the rise of a select group of heavyweights, affectionately called the GRANOLAS. Coined by Goldman Sachs, this nickname refers to eleven European companies that have eclipsed the broader stock market’s performance in recent years. In this blog post, we will delve into who the GRANOLAS are and why they have become Europe’s magnificent stocks.
Source: Dreamstime
Reading time: 8 minutes
Sixty-two per cent. Ninety-four point five per cent. Ninety-seven per cent. In recent months, the released data on the high efficacy rates and the approval of several vaccines has sparked hope that the repressive reign of SARS-CoV-2 is about to end sooner than expected.
But is this really the case or do we still have a long way to go until we beat the pandemic?
Source: DeltaStock
Reading time: 6 minutes
With over 34 million infected and 1 million deaths globally, the race for who will first develop a suitable vaccine against the coronavirus is more disputed than ever. At the moment, thousands of investors have flocked to the biotechnological sector where, according to the World Health Organization, as of July there are 173 potential vaccine developers hard at work, while research expenses have reached billions of U.S. dollars.
Source: Pixabay | Owner: MasterTux
Reading time: six minutes
The world has entered the second half of 2020 just as troubled (if not more so) as it did in the first half. And as financial forecasts grow grimmer by the day, one thing is starting to become painfully clear to all—we might not see a full recovery in 2020, and even one happening in 2021 would depend on a lot going right.